nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirabegron—SLCO1A2—Prednisone—systemic scleroderma	0.121	0.16	CbGbCtD
Mirabegron—ALB—Captopril—systemic scleroderma	0.0992	0.131	CbGbCtD
Mirabegron—ALB—Mycophenolate mofetil—systemic scleroderma	0.0781	0.103	CbGbCtD
Mirabegron—ABCB1—Lisinopril—systemic scleroderma	0.0693	0.0916	CbGbCtD
Mirabegron—ALB—Prednisone—systemic scleroderma	0.0624	0.0825	CbGbCtD
Mirabegron—SLCO1A2—Methotrexate—systemic scleroderma	0.0606	0.0801	CbGbCtD
Mirabegron—ABCB1—Captopril—systemic scleroderma	0.0519	0.0686	CbGbCtD
Mirabegron—CYP2D6—Captopril—systemic scleroderma	0.0489	0.0646	CbGbCtD
Mirabegron—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0408	0.054	CbGbCtD
Mirabegron—ABCB1—Prednisone—systemic scleroderma	0.0327	0.0432	CbGbCtD
Mirabegron—ALB—Methotrexate—systemic scleroderma	0.0313	0.0414	CbGbCtD
Mirabegron—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0245	0.0324	CbGbCtD
Mirabegron—CYP3A4—Prednisone—systemic scleroderma	0.0196	0.0259	CbGbCtD
Mirabegron—ABCB1—Methotrexate—systemic scleroderma	0.0164	0.0217	CbGbCtD
Mirabegron—Rhinitis—Mycophenolic acid—systemic scleroderma	0.000745	0.00306	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Lisinopril—systemic scleroderma	0.000739	0.00303	CcSEcCtD
Mirabegron—Abdominal distension—Mycophenolate mofetil—systemic scleroderma	0.000737	0.00303	CcSEcCtD
Mirabegron—Erythema multiforme—Leflunomide—systemic scleroderma	0.000736	0.00302	CcSEcCtD
Mirabegron—Urinary tract disorder—Mycophenolic acid—systemic scleroderma	0.000733	0.00301	CcSEcCtD
Mirabegron—Influenza—Mycophenolate mofetil—systemic scleroderma	0.000732	0.00301	CcSEcCtD
Mirabegron—Connective tissue disorder—Mycophenolic acid—systemic scleroderma	0.00073	0.003	CcSEcCtD
Mirabegron—Urethral disorder—Mycophenolic acid—systemic scleroderma	0.000728	0.00299	CcSEcCtD
Mirabegron—Eye disorder—Leflunomide—systemic scleroderma	0.000728	0.00299	CcSEcCtD
Mirabegron—Palpitations—Captopril—systemic scleroderma	0.000727	0.00298	CcSEcCtD
Mirabegron—Urinary tract infection—Lisinopril—systemic scleroderma	0.000724	0.00297	CcSEcCtD
Mirabegron—Gastrointestinal pain—Pentoxifylline—systemic scleroderma	0.000724	0.00297	CcSEcCtD
Mirabegron—Cardiac disorder—Leflunomide—systemic scleroderma	0.000723	0.00297	CcSEcCtD
Mirabegron—Urticaria—Pentoxifylline—systemic scleroderma	0.000703	0.00289	CcSEcCtD
Mirabegron—Arthralgia—Captopril—systemic scleroderma	0.0007	0.00287	CcSEcCtD
Mirabegron—Abdominal pain—Pentoxifylline—systemic scleroderma	0.0007	0.00287	CcSEcCtD
Mirabegron—Sinusitis—Lisinopril—systemic scleroderma	0.000699	0.00287	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Mometasone—systemic scleroderma	0.000696	0.00286	CcSEcCtD
Mirabegron—Eye disorder—Mycophenolic acid—systemic scleroderma	0.000694	0.00285	CcSEcCtD
Mirabegron—Cardiac disorder—Mycophenolic acid—systemic scleroderma	0.000689	0.00283	CcSEcCtD
Mirabegron—Dry mouth—Captopril—systemic scleroderma	0.000685	0.00281	CcSEcCtD
Mirabegron—Dyspepsia—Mometasone—systemic scleroderma	0.000673	0.00276	CcSEcCtD
Mirabegron—Rhinitis—Lisinopril—systemic scleroderma	0.000671	0.00275	CcSEcCtD
Mirabegron—Urinary tract disorder—Lisinopril—systemic scleroderma	0.000661	0.00271	CcSEcCtD
Mirabegron—Fatigue—Mometasone—systemic scleroderma	0.000659	0.0027	CcSEcCtD
Mirabegron—Urethral disorder—Lisinopril—systemic scleroderma	0.000656	0.00269	CcSEcCtD
Mirabegron—Back pain—Leflunomide—systemic scleroderma	0.000656	0.00269	CcSEcCtD
Mirabegron—Tachycardia—Captopril—systemic scleroderma	0.000655	0.00269	CcSEcCtD
Mirabegron—Infestation NOS—Mycophenolate mofetil—systemic scleroderma	0.000653	0.00268	CcSEcCtD
Mirabegron—Infestation—Mycophenolate mofetil—systemic scleroderma	0.000653	0.00268	CcSEcCtD
Mirabegron—Cystitis noninfective—Methotrexate—systemic scleroderma	0.000646	0.00265	CcSEcCtD
Mirabegron—Vascular purpura—Prednisone—systemic scleroderma	0.000642	0.00264	CcSEcCtD
Mirabegron—Vision blurred—Leflunomide—systemic scleroderma	0.000639	0.00262	CcSEcCtD
Mirabegron—Cystitis—Methotrexate—systemic scleroderma	0.000638	0.00262	CcSEcCtD
Mirabegron—Asthenia—Pentoxifylline—systemic scleroderma	0.000635	0.00261	CcSEcCtD
Mirabegron—Urinary tract infection—Mycophenolate mofetil—systemic scleroderma	0.000635	0.0026	CcSEcCtD
Mirabegron—Erythema multiforme—Lisinopril—systemic scleroderma	0.000632	0.0026	CcSEcCtD
Mirabegron—Pruritus—Pentoxifylline—systemic scleroderma	0.000626	0.00257	CcSEcCtD
Mirabegron—Back pain—Mycophenolic acid—systemic scleroderma	0.000625	0.00257	CcSEcCtD
Mirabegron—Gastrointestinal pain—Mometasone—systemic scleroderma	0.000625	0.00256	CcSEcCtD
Mirabegron—Vaginal infection—Methotrexate—systemic scleroderma	0.000624	0.00256	CcSEcCtD
Mirabegron—Sinusitis—Mycophenolate mofetil—systemic scleroderma	0.000613	0.00251	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Captopril—systemic scleroderma	0.000611	0.00251	CcSEcCtD
Mirabegron—Arthralgia—Azathioprine—systemic scleroderma	0.000611	0.00251	CcSEcCtD
Mirabegron—Vision blurred—Mycophenolic acid—systemic scleroderma	0.000609	0.0025	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.000607	0.00249	CcSEcCtD
Mirabegron—Diarrhoea—Pentoxifylline—systemic scleroderma	0.000606	0.00249	CcSEcCtD
Mirabegron—Abdominal pain—Mometasone—systemic scleroderma	0.000604	0.00248	CcSEcCtD
Mirabegron—Palpitations—Leflunomide—systemic scleroderma	0.000599	0.00246	CcSEcCtD
Mirabegron—Neoplasm—Methotrexate—systemic scleroderma	0.000598	0.00245	CcSEcCtD
Mirabegron—Bladder pain—Methotrexate—systemic scleroderma	0.000598	0.00245	CcSEcCtD
Mirabegron—Purpura—Prednisone—systemic scleroderma	0.000596	0.00245	CcSEcCtD
Mirabegron—Dyspepsia—Captopril—systemic scleroderma	0.000591	0.00242	CcSEcCtD
Mirabegron—Rhinitis—Mycophenolate mofetil—systemic scleroderma	0.000588	0.00241	CcSEcCtD
Mirabegron—Dizziness—Pentoxifylline—systemic scleroderma	0.000586	0.0024	CcSEcCtD
Mirabegron—Hypertension—Leflunomide—systemic scleroderma	0.000585	0.0024	CcSEcCtD
Mirabegron—Infection—Azathioprine—systemic scleroderma	0.000582	0.00239	CcSEcCtD
Mirabegron—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.000579	0.00238	CcSEcCtD
Mirabegron—Fatigue—Captopril—systemic scleroderma	0.000579	0.00237	CcSEcCtD
Mirabegron—Arthralgia—Leflunomide—systemic scleroderma	0.000577	0.00237	CcSEcCtD
Mirabegron—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.000576	0.00236	CcSEcCtD
Mirabegron—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.000575	0.00236	CcSEcCtD
Mirabegron—Osteoarthritis—Prednisone—systemic scleroderma	0.000574	0.00236	CcSEcCtD
Mirabegron—Constipation—Captopril—systemic scleroderma	0.000574	0.00236	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000573	0.00235	CcSEcCtD
Mirabegron—Palpitations—Mycophenolic acid—systemic scleroderma	0.000571	0.00235	CcSEcCtD
Mirabegron—Skin disorder—Azathioprine—systemic scleroderma	0.000569	0.00234	CcSEcCtD
Mirabegron—Dry mouth—Leflunomide—systemic scleroderma	0.000564	0.00232	CcSEcCtD
Mirabegron—Back pain—Lisinopril—systemic scleroderma	0.000563	0.00231	CcSEcCtD
Mirabegron—Rash—Pentoxifylline—systemic scleroderma	0.000558	0.00229	CcSEcCtD
Mirabegron—Hypertension—Mycophenolic acid—systemic scleroderma	0.000558	0.00229	CcSEcCtD
Mirabegron—Dermatitis—Pentoxifylline—systemic scleroderma	0.000558	0.00229	CcSEcCtD
Mirabegron—Headache—Pentoxifylline—systemic scleroderma	0.000555	0.00228	CcSEcCtD
Mirabegron—Arthralgia—Mycophenolic acid—systemic scleroderma	0.00055	0.00226	CcSEcCtD
Mirabegron—Infection—Leflunomide—systemic scleroderma	0.000549	0.00226	CcSEcCtD
Mirabegron—Vision blurred—Lisinopril—systemic scleroderma	0.000549	0.00225	CcSEcCtD
Mirabegron—Gastrointestinal pain—Captopril—systemic scleroderma	0.000549	0.00225	CcSEcCtD
Mirabegron—Asthenia—Mometasone—systemic scleroderma	0.000548	0.00225	CcSEcCtD
Mirabegron—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000548	0.00225	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000547	0.00224	CcSEcCtD
Mirabegron—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000544	0.00223	CcSEcCtD
Mirabegron—Pruritus—Mometasone—systemic scleroderma	0.000541	0.00222	CcSEcCtD
Mirabegron—Tachycardia—Leflunomide—systemic scleroderma	0.00054	0.00222	CcSEcCtD
Mirabegron—Dry mouth—Mycophenolic acid—systemic scleroderma	0.000538	0.00221	CcSEcCtD
Mirabegron—Skin disorder—Leflunomide—systemic scleroderma	0.000537	0.00221	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000534	0.00219	CcSEcCtD
Mirabegron—Abdominal pain—Captopril—systemic scleroderma	0.000531	0.00218	CcSEcCtD
Mirabegron—Nausea—Pentoxifylline—systemic scleroderma	0.000526	0.00216	CcSEcCtD
Mirabegron—Infection—Mycophenolic acid—systemic scleroderma	0.000524	0.00215	CcSEcCtD
Mirabegron—Diarrhoea—Mometasone—systemic scleroderma	0.000523	0.00215	CcSEcCtD
Mirabegron—Tachycardia—Mycophenolic acid—systemic scleroderma	0.000515	0.00211	CcSEcCtD
Mirabegron—Palpitations—Lisinopril—systemic scleroderma	0.000515	0.00211	CcSEcCtD
Mirabegron—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000513	0.0021	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000507	0.00208	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000506	0.00208	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000504	0.00207	CcSEcCtD
Mirabegron—Abdominal distension—Prednisone—systemic scleroderma	0.0005	0.00205	CcSEcCtD
Mirabegron—Arthralgia—Lisinopril—systemic scleroderma	0.000496	0.00203	CcSEcCtD
Mirabegron—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000494	0.00203	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000492	0.00202	CcSEcCtD
Mirabegron—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.00049	0.00201	CcSEcCtD
Mirabegron—Dyspepsia—Leflunomide—systemic scleroderma	0.000487	0.002	CcSEcCtD
Mirabegron—Dry mouth—Lisinopril—systemic scleroderma	0.000485	0.00199	CcSEcCtD
Mirabegron—Rash—Mometasone—systemic scleroderma	0.000482	0.00198	CcSEcCtD
Mirabegron—Asthenia—Captopril—systemic scleroderma	0.000481	0.00198	CcSEcCtD
Mirabegron—Dermatitis—Mometasone—systemic scleroderma	0.000481	0.00198	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000481	0.00197	CcSEcCtD
Mirabegron—Osteoarthritis—Methotrexate—systemic scleroderma	0.00048	0.00197	CcSEcCtD
Mirabegron—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000479	0.00197	CcSEcCtD
Mirabegron—Headache—Mometasone—systemic scleroderma	0.000479	0.00196	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000478	0.00196	CcSEcCtD
Mirabegron—Fatigue—Leflunomide—systemic scleroderma	0.000477	0.00196	CcSEcCtD
Mirabegron—Pruritus—Captopril—systemic scleroderma	0.000475	0.00195	CcSEcCtD
Mirabegron—Constipation—Leflunomide—systemic scleroderma	0.000473	0.00194	CcSEcCtD
Mirabegron—Infection—Lisinopril—systemic scleroderma	0.000472	0.00194	CcSEcCtD
Mirabegron—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000464	0.00191	CcSEcCtD
Mirabegron—Tachycardia—Lisinopril—systemic scleroderma	0.000464	0.0019	CcSEcCtD
Mirabegron—Abdominal pain—Azathioprine—systemic scleroderma	0.000463	0.0019	CcSEcCtD
Mirabegron—Skin disorder—Lisinopril—systemic scleroderma	0.000462	0.00189	CcSEcCtD
Mirabegron—Diarrhoea—Captopril—systemic scleroderma	0.000459	0.00188	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000456	0.00187	CcSEcCtD
Mirabegron—Fatigue—Mycophenolic acid—systemic scleroderma	0.000455	0.00187	CcSEcCtD
Mirabegron—Nausea—Mometasone—systemic scleroderma	0.000454	0.00186	CcSEcCtD
Mirabegron—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000452	0.00186	CcSEcCtD
Mirabegron—Constipation—Mycophenolic acid—systemic scleroderma	0.000451	0.00185	CcSEcCtD
Mirabegron—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000451	0.00185	CcSEcCtD
Mirabegron—Dizziness—Captopril—systemic scleroderma	0.000444	0.00182	CcSEcCtD
Mirabegron—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000441	0.00181	CcSEcCtD
Mirabegron—Urticaria—Leflunomide—systemic scleroderma	0.000439	0.0018	CcSEcCtD
Mirabegron—Abdominal pain—Leflunomide—systemic scleroderma	0.000437	0.00179	CcSEcCtD
Mirabegron—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000434	0.00178	CcSEcCtD
Mirabegron—Breast disorder—Methotrexate—systemic scleroderma	0.000434	0.00178	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000433	0.00178	CcSEcCtD
Mirabegron—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000431	0.00177	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000431	0.00177	CcSEcCtD
Mirabegron—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000425	0.00174	CcSEcCtD
Mirabegron—Rash—Captopril—systemic scleroderma	0.000423	0.00174	CcSEcCtD
Mirabegron—Dermatitis—Captopril—systemic scleroderma	0.000423	0.00174	CcSEcCtD
Mirabegron—Headache—Captopril—systemic scleroderma	0.00042	0.00173	CcSEcCtD
Mirabegron—Dyspepsia—Lisinopril—systemic scleroderma	0.000418	0.00172	CcSEcCtD
Mirabegron—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000417	0.00171	CcSEcCtD
Mirabegron—Infection—Mycophenolate mofetil—systemic scleroderma	0.000414	0.0017	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00041	0.00168	CcSEcCtD
Mirabegron—Fatigue—Lisinopril—systemic scleroderma	0.00041	0.00168	CcSEcCtD
Mirabegron—Constipation—Lisinopril—systemic scleroderma	0.000406	0.00167	CcSEcCtD
Mirabegron—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000406	0.00167	CcSEcCtD
Mirabegron—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000404	0.00166	CcSEcCtD
Mirabegron—Diarrhoea—Azathioprine—systemic scleroderma	0.000401	0.00164	CcSEcCtD
Mirabegron—Nausea—Captopril—systemic scleroderma	0.000399	0.00164	CcSEcCtD
Mirabegron—Asthenia—Leflunomide—systemic scleroderma	0.000397	0.00163	CcSEcCtD
Mirabegron—Pruritus—Leflunomide—systemic scleroderma	0.000391	0.00161	CcSEcCtD
Mirabegron—Connective tissue disorder—Prednisone—systemic scleroderma	0.00039	0.0016	CcSEcCtD
Mirabegron—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000389	0.0016	CcSEcCtD
Mirabegron—Dizziness—Azathioprine—systemic scleroderma	0.000387	0.00159	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000386	0.00158	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000379	0.00156	CcSEcCtD
Mirabegron—Asthenia—Mycophenolic acid—systemic scleroderma	0.000379	0.00155	CcSEcCtD
Mirabegron—Diarrhoea—Leflunomide—systemic scleroderma	0.000378	0.00155	CcSEcCtD
Mirabegron—Urticaria—Lisinopril—systemic scleroderma	0.000378	0.00155	CcSEcCtD
Mirabegron—Abdominal pain—Lisinopril—systemic scleroderma	0.000376	0.00154	CcSEcCtD
Mirabegron—Pruritus—Mycophenolic acid—systemic scleroderma	0.000373	0.00153	CcSEcCtD
Mirabegron—Eye disorder—Prednisone—systemic scleroderma	0.000371	0.00152	CcSEcCtD
Mirabegron—Infestation—Methotrexate—systemic scleroderma	0.00037	0.00152	CcSEcCtD
Mirabegron—Infestation NOS—Methotrexate—systemic scleroderma	0.00037	0.00152	CcSEcCtD
Mirabegron—Rash—Azathioprine—systemic scleroderma	0.000369	0.00152	CcSEcCtD
Mirabegron—Dermatitis—Azathioprine—systemic scleroderma	0.000369	0.00151	CcSEcCtD
Mirabegron—Headache—Azathioprine—systemic scleroderma	0.000367	0.00151	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000367	0.00151	CcSEcCtD
Mirabegron—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000367	0.0015	CcSEcCtD
Mirabegron—Dizziness—Leflunomide—systemic scleroderma	0.000366	0.0015	CcSEcCtD
Mirabegron—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000361	0.00148	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000359	0.00148	CcSEcCtD
Mirabegron—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000356	0.00146	CcSEcCtD
Mirabegron—Dizziness—Mycophenolic acid—systemic scleroderma	0.000349	0.00143	CcSEcCtD
Mirabegron—Rash—Leflunomide—systemic scleroderma	0.000349	0.00143	CcSEcCtD
Mirabegron—Dermatitis—Leflunomide—systemic scleroderma	0.000348	0.00143	CcSEcCtD
Mirabegron—Nausea—Azathioprine—systemic scleroderma	0.000348	0.00143	CcSEcCtD
Mirabegron—Headache—Leflunomide—systemic scleroderma	0.000346	0.00142	CcSEcCtD
Mirabegron—Asthenia—Lisinopril—systemic scleroderma	0.000341	0.0014	CcSEcCtD
Mirabegron—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000341	0.0014	CcSEcCtD
Mirabegron—Pruritus—Lisinopril—systemic scleroderma	0.000336	0.00138	CcSEcCtD
Mirabegron—Rash—Mycophenolic acid—systemic scleroderma	0.000333	0.00137	CcSEcCtD
Mirabegron—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000332	0.00136	CcSEcCtD
Mirabegron—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000331	0.00136	CcSEcCtD
Mirabegron—Headache—Mycophenolic acid—systemic scleroderma	0.000331	0.00136	CcSEcCtD
Mirabegron—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000329	0.00135	CcSEcCtD
Mirabegron—Nausea—Leflunomide—systemic scleroderma	0.000329	0.00135	CcSEcCtD
Mirabegron—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000328	0.00135	CcSEcCtD
Mirabegron—Vision blurred—Prednisone—systemic scleroderma	0.000326	0.00134	CcSEcCtD
Mirabegron—Urethral disorder—Methotrexate—systemic scleroderma	0.000325	0.00134	CcSEcCtD
Mirabegron—Diarrhoea—Lisinopril—systemic scleroderma	0.000325	0.00133	CcSEcCtD
Mirabegron—Dizziness—Lisinopril—systemic scleroderma	0.000314	0.00129	CcSEcCtD
Mirabegron—Erythema multiforme—Methotrexate—systemic scleroderma	0.000314	0.00129	CcSEcCtD
Mirabegron—Nausea—Mycophenolic acid—systemic scleroderma	0.000313	0.00129	CcSEcCtD
Mirabegron—Eye disorder—Methotrexate—systemic scleroderma	0.00031	0.00127	CcSEcCtD
Mirabegron—Cardiac disorder—Methotrexate—systemic scleroderma	0.000308	0.00126	CcSEcCtD
Mirabegron—Rash—Lisinopril—systemic scleroderma	0.0003	0.00123	CcSEcCtD
Mirabegron—Dermatitis—Lisinopril—systemic scleroderma	0.000299	0.00123	CcSEcCtD
Mirabegron—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000299	0.00123	CcSEcCtD
Mirabegron—Hypertension—Prednisone—systemic scleroderma	0.000299	0.00123	CcSEcCtD
Mirabegron—Headache—Lisinopril—systemic scleroderma	0.000298	0.00122	CcSEcCtD
Mirabegron—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000295	0.00121	CcSEcCtD
Mirabegron—Arthralgia—Prednisone—systemic scleroderma	0.000294	0.00121	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000292	0.0012	CcSEcCtD
Mirabegron—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000285	0.00117	CcSEcCtD
Mirabegron—Nausea—Lisinopril—systemic scleroderma	0.000282	0.00116	CcSEcCtD
Mirabegron—Infection—Prednisone—systemic scleroderma	0.00028	0.00115	CcSEcCtD
Mirabegron—Back pain—Methotrexate—systemic scleroderma	0.00028	0.00115	CcSEcCtD
Mirabegron—Tachycardia—Prednisone—systemic scleroderma	0.000275	0.00113	CcSEcCtD
Mirabegron—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000275	0.00113	CcSEcCtD
Mirabegron—Skin disorder—Prednisone—systemic scleroderma	0.000274	0.00113	CcSEcCtD
Mirabegron—Vision blurred—Methotrexate—systemic scleroderma	0.000272	0.00112	CcSEcCtD
Mirabegron—Rash—Mycophenolate mofetil—systemic scleroderma	0.000263	0.00108	CcSEcCtD
Mirabegron—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000262	0.00108	CcSEcCtD
Mirabegron—Headache—Mycophenolate mofetil—systemic scleroderma	0.000261	0.00107	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000257	0.00106	CcSEcCtD
Mirabegron—Dyspepsia—Prednisone—systemic scleroderma	0.000248	0.00102	CcSEcCtD
Mirabegron—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000247	0.00102	CcSEcCtD
Mirabegron—Arthralgia—Methotrexate—systemic scleroderma	0.000246	0.00101	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000244	0.001	CcSEcCtD
Mirabegron—Fatigue—Prednisone—systemic scleroderma	0.000243	0.000999	CcSEcCtD
Mirabegron—Constipation—Prednisone—systemic scleroderma	0.000241	0.000991	CcSEcCtD
Mirabegron—Infection—Methotrexate—systemic scleroderma	0.000234	0.000962	CcSEcCtD
Mirabegron—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000231	0.000947	CcSEcCtD
Mirabegron—Skin disorder—Methotrexate—systemic scleroderma	0.000229	0.00094	CcSEcCtD
Mirabegron—Urticaria—Prednisone—systemic scleroderma	0.000224	0.00092	CcSEcCtD
Mirabegron—Abdominal pain—Prednisone—systemic scleroderma	0.000223	0.000916	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000215	0.000882	CcSEcCtD
Mirabegron—Dyspepsia—Methotrexate—systemic scleroderma	0.000208	0.000852	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000204	0.000836	CcSEcCtD
Mirabegron—Fatigue—Methotrexate—systemic scleroderma	0.000203	0.000835	CcSEcCtD
Mirabegron—Asthenia—Prednisone—systemic scleroderma	0.000203	0.000831	CcSEcCtD
Mirabegron—Pruritus—Prednisone—systemic scleroderma	0.0002	0.00082	CcSEcCtD
Mirabegron—Diarrhoea—Prednisone—systemic scleroderma	0.000193	0.000793	CcSEcCtD
Mirabegron—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000193	0.000792	CcSEcCtD
Mirabegron—Urticaria—Methotrexate—systemic scleroderma	0.000187	0.000769	CcSEcCtD
Mirabegron—Dizziness—Prednisone—systemic scleroderma	0.000187	0.000766	CcSEcCtD
Mirabegron—Abdominal pain—Methotrexate—systemic scleroderma	0.000186	0.000765	CcSEcCtD
Mirabegron—Rash—Prednisone—systemic scleroderma	0.000178	0.00073	CcSEcCtD
Mirabegron—Dermatitis—Prednisone—systemic scleroderma	0.000178	0.00073	CcSEcCtD
Mirabegron—Headache—Prednisone—systemic scleroderma	0.000177	0.000726	CcSEcCtD
Mirabegron—Asthenia—Methotrexate—systemic scleroderma	0.000169	0.000695	CcSEcCtD
Mirabegron—Nausea—Prednisone—systemic scleroderma	0.000168	0.000688	CcSEcCtD
Mirabegron—Pruritus—Methotrexate—systemic scleroderma	0.000167	0.000685	CcSEcCtD
Mirabegron—Diarrhoea—Methotrexate—systemic scleroderma	0.000161	0.000662	CcSEcCtD
Mirabegron—Dizziness—Methotrexate—systemic scleroderma	0.000156	0.00064	CcSEcCtD
Mirabegron—Rash—Methotrexate—systemic scleroderma	0.000149	0.00061	CcSEcCtD
Mirabegron—Dermatitis—Methotrexate—systemic scleroderma	0.000149	0.00061	CcSEcCtD
Mirabegron—Headache—Methotrexate—systemic scleroderma	0.000148	0.000607	CcSEcCtD
Mirabegron—Nausea—Methotrexate—systemic scleroderma	0.00014	0.000575	CcSEcCtD
